{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fher2-targeted-adcs-in-solid-tumors-hmyHtaoK","width":444,"version":"1.0","type":"rich","title":"The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/5b6edf3d-9adc-41fc-bea3-04d9475846a5/100524-multitumor-her2-pod01-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/009ae19b-bc72-4c2e-ac6c-5f07395b4551\" height=\"200\" width=\"100%\" title=\"The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"This podcast explores the expanding role of HER2-targeted ADCs across genitourinary, gastrointestinal, and gynecologic cancers. Experts discuss HER2 alterations, molecular testing strategies, and emerging clinical data."}